MBL HCV1

Drug Profile

MBL HCV1

Alternative Names: MBL-HCV1

Latest Information Update: 03 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MassBiologics
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Hepatitis C virus envelope protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 19 Feb 2016 MassBiologics terminates a phase II trial in Hepatitis C in USA (NCT01121185)
  • 12 Feb 2016 MassBiologics terminates phase II trial in Hepatitis C in the US (NCT01532908)
  • 14 Sep 2015 Phase-II development for Hepatitis C is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top